Modeling Disease Progression in Mild Cognitive Impairment and Alzheimer's Disease with Digital Twins

Alzheimer's Disease (AD) is a neurodegenerative disease that affects subjects in a broad range of severity and is assessed in clinical trials with multiple cognitive and functional instruments. As clinical trials in AD increasingly focus on earlier stages of the disease, especially Mild Cognitive Impairment (MCI), the ability to model subject outcomes across the disease spectrum is extremely important. We use unsupervised machine learning models called Conditional Restricted Boltzmann Machines (CRBMs) to create Digital Twins of AD subjects. Digital Twins are simulated clinical records that share baseline data with actual subjects and comprehensively model their outcomes under standard-of-care. The CRBMs are trained on a large set of records from subjects in observational studies and the placebo arms of clinical trials across the AD spectrum. These data exhibit a challenging, but common, patchwork of measured and missing observations across subjects in the dataset, and we present a novel model architecture designed to learn effectively from it. We evaluate performance against a held-out test dataset and show how Digital Twins simultaneously capture the progression of a number of key endpoints in clinical trials across a broad spectrum of disease severity, including MCI and mild-to-moderate AD.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Press

Unlearn.AI named to the 2021 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups

Blog

Welcoming Dr. Taylor to Unlearn.AI’s Board of Directors

Press

Unlearn Appoints AstraZeneca’s Chief Medical Officer Ann E. Taylor, M.D. to Board of Directors

Ann E. Taylor, M.D., Chief Medical Officer at AstraZeneca, has joined the Unlearn Board of Directors.
I’m honored to have such an inspirational and experienced leader like Dr. Taylor join our board.
The AI 100 is CB Insights' annual list of the 100 most promising private AI companies in the world.